1. Introduction {#sec1-ijms-18-00854}
===============

Early brain injury (EBI) refers to the direct brain damage that occurs within 72 h after bleeding and is considered to be the major factor of poor prognosis after subarachnoid haemorrhage (SAH) \[[@B1-ijms-18-00854]\]. Previous studies have confirmed that brain cell apoptosis occurs after SAH and that the levels of numerous apoptotic proteins increased during this process \[[@B2-ijms-18-00854],[@B3-ijms-18-00854]\]. Apoptosis has gradually become regarded as the most important pathological event in aggravating brain cell death, blood-brain barrier (BBB) disruption, and brain edema after SAH \[[@B1-ijms-18-00854]\]. Although some anti-apoptotic strategies have been developed in EBI treatment, the mortality and disability of SAH still remain high, indicating that there may be some unknown mechanisms.

Thioredoxin-interacting protein (TXNIP), also named thioredoxin binding protein-2 or vitamin D3 upregulated protein-1, is widely expressed in the nucleus, mitochondria, and cytoplasm of normal tissue cells \[[@B4-ijms-18-00854]\]. TXNIP directly binds to the active cysteine residue of thioredoxin (TRX) under pathological conditions and further disturbs the TRX/apoptosis signal-regulating kinase-1 (ASK-1) inhibitory complex. This disruption leads to ASK-1 release and activation of the downstream cascade of the apoptosis signalling pathway \[[@B5-ijms-18-00854]\]. Meanwhile, previous studies have found that TXNIP participates in ischaemic diseases \[[@B6-ijms-18-00854],[@B7-ijms-18-00854]\]. Apoptosis is important during EBI, but whether or not TXNIP participates in EBI by mediating apoptosis has not been explored. We previously found that silencing the downstream protein of the protein kinase RNA-like endoplasmic reticulum (ER) kinase (PERK) downstream protein could reduce neuronal apoptosis after SAH \[[@B3-ijms-18-00854]\]. Coincidentally, researchers have recently discovered that PERK, a transmembrane protein in the ER, significantly promotes TXNIP expression \[[@B8-ijms-18-00854]\]. According to these observations, we hypothesized that PERK-induced TXNIP expression may be involved in EBI through its pro-apoptotic function. Therefore, we utilized a TXNIP inhibitor, small interfering RNA (siRNA), and PERK-specific inhibitor to suppress the activity of TXNIP or PERK to confirm that the inhibition of PERK-induced TXNIP expression may exert anti-apoptotic and neuroprotective effects after SAH.

2. Results {#sec2-ijms-18-00854}
==========

2.1. TXNIP Expression Increased Obviously after SAH {#sec2dot1-ijms-18-00854}
---------------------------------------------------

To confirm our speculation, we designed the experiments shown in [Figure 1](#ijms-18-00854-f001){ref-type="fig"}. Here, rats were divided into different groups, as described in the methods below: sham, SAH, SAH + control siRNA (Control), SAH + TXNIP siRNA, SAH + normal saline (NS), SAH + resveratrol (RES), SAH + dimethyl sulfoxide (DMSO, as a vehicle), and SAH + GSK2656157 (GSK). Both siRNA and GSK2656157 were injected through intracerebroventricular infusion, and RES was administered via intraperitoneal injection.

First, to detect SAH-induced changes in TXNIP expression and apoptosis, we created SAH models and performed a western blot analysis of the expression of TXNIP, TRX1, p-ASK-1/ASK-1, cleaved caspase-3 (CC3), B-cell lymphoma (BCL)-2-associated X protein (BAX), and BCL-2 at different time intervals (*n* = 6 in each group). Both CC3 and BAX are common apoptosis indexes, while TRX1 and BCL-2 are anti-apoptotic proteins \[[@B9-ijms-18-00854],[@B10-ijms-18-00854]\]. We found that TXNIP expression increased significantly after SAH ([Figure 2](#ijms-18-00854-f002){ref-type="fig"}A,B) at 24 h (0.31 ± 0.02) in comparison to the sham group (0.15 ± 0.05) and peaked at 48 h (0.48 ± 0.04, up to 3.2-fold, *p* = 0.007). The expression of p-ASK-1/ASK-1 (*p* = 0.014), CC3 (*p* = 0.002), and BAX (*p* = 0.000) was also elevated to different extents, accompanied by the downregulation of TRX1 (*p* = 0.023) and BCL-2 (*p* = 0.008) ([Figure 2](#ijms-18-00854-f002){ref-type="fig"}A,C--G). These results indicated that SAH significantly promoted the expression of TXNIP and apoptosis proteins.

2.2. TXNIP Was Expressed in Neurons and Is Colocalized with TUNEL Positive Cells {#sec2dot2-ijms-18-00854}
--------------------------------------------------------------------------------

Based on our previous clinical and experimental observations, clinical symptoms appear and are significant at 24 h in patients and animals after intracranial aneurysm bleeding and SAH. Meanwhile, in our previous study, we detected significant brain cell apoptosis at 24 h and usually remove the brain tissue at 24 h \[[@B3-ijms-18-00854],[@B11-ijms-18-00854]\]. As such, at the beginning of the experimental design, we aimed to observe the results at 24 h in the following experiments, including immunofluorescence, western blot, and apoptosis detection. In addition, we found that changes in TXNIP expression began at 12 h and were obvious at 48 h. At the same time, differences in TXNIP expression at 24 h was also significant when compared with the sham group. Therefore, the results of immunofluorescence, western blot, and apoptosis detection at 24 h may also provide powerful evidence to support research conclusions.

Because a previous study reported TXNIP expression in neurons of ischaemic--reperfusion brains \[[@B12-ijms-18-00854]\], we also investigated the tissue expression of TXNIP after SAH. Immunofluorescence was performed to detect the localization of TXNIP in the SAH rat brain. Our results showed that TXNIP was widely expressed in the cytoplasm of neurons after SAH (*n* = 3, [Figure 3](#ijms-18-00854-f003){ref-type="fig"}A). To confirm that TXNIP was associated with brain cell apoptosis after SAH, we used Terminal dexynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) staining, a marker for apoptotic cell death \[[@B13-ijms-18-00854]\]. Interestingly, TUNEL analysis demonstrated for the first time that TXNIP was widely colocalized with TUNEL-positive cells in both the hippocampus and cortex of SAH rats (*n* = 3, [Figure 3](#ijms-18-00854-f003){ref-type="fig"}B). These results may provide the critical evidence necessary to support the proapoptotic effect of TXNIP after SAH.

2.3. Downregulation of TXNIP by Resveratrol (RES) and siRNA {#sec2dot3-ijms-18-00854}
-----------------------------------------------------------

To further confirm our hypothesis that TXNIP induces apoptosis after SAH, we used RES and TXNIP siRNA to downregulate TXNIP expression. RES is reported to have anti-apoptotic, anti-oxidative, and anti-inflammatory properties \[[@B14-ijms-18-00854]\] and is the most commonly reported strategy to suppress TXNIP and mRNA expression in animal experiments \[[@B7-ijms-18-00854],[@B15-ijms-18-00854]\]. We detected that TXNIP expression increased at 24 h (0.41 ± 0.01) in comparison to the sham group ([Figure 4](#ijms-18-00854-f004){ref-type="fig"}D,E, 0.08 ± 0.01, *p* = 0.001). We found that TXNIP blockage by RES in SAH could significantly reduce the generation of apoptosis proteins ([Figure 4](#ijms-18-00854-f004){ref-type="fig"}D). Meanwhile, RES prevented SAH-induced brain injury and was associated with the reduced expression of TXNIP (*p* = 0.01), p-ASK-1 (*p* = 0.005), CC3 (*p* = 0.000), and BAX (*p* = 0.001) and the increased expression of TRX1 (*p* = 0.000) and BCL-2 (*p* = 0.001) at 24 h after SAH ([Figure 4](#ijms-18-00854-f004){ref-type="fig"}D--F and [Figure S2](#app1-ijms-18-00854){ref-type="app"}). Brain cell apoptosis was analysed by counting the number of TUNEL-positive cells (*n* = 5), and the number of TUNEL-positive cells in the cortex was reduced by RES injection (*p* \< 0.05, [Figure 4](#ijms-18-00854-f004){ref-type="fig"}G,H).

Although TXNIP is a promising therapeutic target, it lacks specific inhibitors and agonists. Additionally, we cannot exclude the possibility that some other mechanisms may also mediate the protection observed with RES treatment, as some researchers have reported that RES may reduce cell apoptosis through the activation of some anti-apoptotic pathways \[[@B16-ijms-18-00854]\]. Thus, we further utilized two previously reported siRNA mixtures to knockdown TXNIP expression \[[@B17-ijms-18-00854],[@B18-ijms-18-00854]\]. We also found that TXNIP expression increased at 24 h (0.31 ± 0.02) in comparison to the sham group ([Figure 4](#ijms-18-00854-f004){ref-type="fig"}A,B, 0.12 ± 0.01, *p* = 0.009). The results showed that TXNIP expression was significantly downregulated by siRNA injection (*p* = 0.003, [Figure 4](#ijms-18-00854-f004){ref-type="fig"}A,B). TXNIP siRNA also decreased the expression of p-ASK-1(*p* = 0.001), CC3 (*p* = 0.001), and BAX (*p* = 0.024), accompanied by an enhanced expression of TRX1 (*p* = 0.001) and BCL-2 (*p* = 0.032) ([Figure 4](#ijms-18-00854-f004){ref-type="fig"}A--C and [Figure S1](#app1-ijms-18-00854){ref-type="app"}). The number of TUNEL-positive cells was also significantly reduced (*p* \< 0.05, [Figure 4](#ijms-18-00854-f004){ref-type="fig"}G,H). Taken together, these results further indicated that TXNIP may aggravate apoptosis after SAH by triggering the downstream apoptosis signalling cascade.

2.4. Downregulation of TXNIP by PERK Inhibition {#sec2dot4-ijms-18-00854}
-----------------------------------------------

Simultaneously, we aimed to determine the potential mechanism regulating TXNIP expression after SAH. Our previous work found that silencing the downstream protein of PERK could reduce neuronal apoptosis after SAH \[[@B3-ijms-18-00854]\]. PERK is expressed in the ER transmembrane and has multiple biological functions in the regulation of cell death \[[@B19-ijms-18-00854]\]. More interestingly, researchers recently found that PERK significantly promoted TXNIP expression under ER stress \[[@B8-ijms-18-00854]\]. Thus, we speculated that these mechanisms may also occur after SAH. Therefore, we first inhibited PERK phosphorylation by injecting its specific inhibitor GSK2656157 through intracerebroventricular infusion. We found that PERK phosphorylation was suppressed by GSK2656157 in a dose-dependent manner after SAH, with a significant inhibitory effect from 120 to 300 μg ([Figure 5](#ijms-18-00854-f005){ref-type="fig"}A,B, *p* = 0.000). Meanwhile, the expression of transcription factors downstream of PERK, including phosphorylated eukaryotic translation initiation factor 2α (eIF2α) (*p* = 0.006), activating transcription factor 5 (ATF-5) (*p* = 0.001), and carbohydrate response element binding protein (ChREBP) (*p* = 0.000) transcription factors, was also reduced ([Figure 5](#ijms-18-00854-f005){ref-type="fig"}A,C--E). We then used 300 μg of GSK2656157 for the following experiments, as this dosage showed significant PERK inhibition. TXNIP expression increased at 24 h (0.32 ± 0.01) in comparison to the sham group ([Figure 6](#ijms-18-00854-f006){ref-type="fig"}A,C, 0.10 ± 0.01, *p* = 0.016). TXNIP expression was significantly suppressed by the GSK2656157 (300 μg) treatment (*p* = 0.020, [Figure 6](#ijms-18-00854-f006){ref-type="fig"}A,C). The number of TUNEL-positive cells also decreased by the GSK2656157 treatment (*p* \< 0.01, [Figure 6](#ijms-18-00854-f006){ref-type="fig"}D,E). These results indirectly suggested that PERK regulates TXNIP expression after SAH. To some extent, PERK inhibition may downregulate TXNIP expression and reduce apoptosis. We found that the PERK phosphorylation was suppressed by GSK2656157.

2.5. SAH Grade and Mortality {#sec2dot5-ijms-18-00854}
----------------------------

Because SAH grade and mortality are prognostic indicators for SAH, they were recorded after surgery and intervention. The SAH grading scores were similar among each surgery group ([Figure 7](#ijms-18-00854-f007){ref-type="fig"}A, *p* = 0.961). A total of 19 rats died during or immediately after operation due to severe SAH, and another 17 rats were excluded because of their low SAH grade. No death was observed in the sham group. Mortality occurred mainly within 24 h after operation. After surgery, 49 rats died within 24 h, and the mortality rates were calculated as follows: 0% (sham, 0 of 33), 23.8% (SAH, 15 of 63), 21.7% (control siRNA, 5 of 23), 14.3% (TXNIP siRNA, 3 of 21), 25.0% (NS, 6 of 24), 18.1% (RES, 4 of 22), 25.0% (DMSO, 7 of 28), and 20.0% (GSK2656157, 9 of 45). However, there were no statistically significant differences in mortality rates between treatment groups after analysis with a Fisher two-sided exact test (*p* = 0.701, control siRNA vs. TXNIP siRNA; *p* = 0.725, NS vs. RES; *p* = 0.772, DMSO vs. GSK2656157).

2.6. Neurological Deficits {#sec2dot6-ijms-18-00854}
--------------------------

Neurological scores were measured to evaluate the prognosis of rats 24 h and 72 h after SAH. We found that SAH significantly induced neurological dysfunction after perforation ([Figure 7](#ijms-18-00854-f007){ref-type="fig"}B,C). Compared with the scores of the sham group (18.00 ± 0.00), the neurological scores in the SAH group were significantly lower at 24 h and 72 h (10.75 ± 0.37, *p* = 0.001 and 12.58 ± 0.36, *p* = 0.003, respectively, *n* = 12, [Figure 7](#ijms-18-00854-f007){ref-type="fig"}B,C). In contrast, there were no significant differences among each control group ([Figure 7](#ijms-18-00854-f007){ref-type="fig"}B,C, *p \>* 0.05). Compared with the scores in the control siRNA group (10.58 ± 0.36 and 12.50 ± 0.38), the neurological scores were improved in the siRNA group at 24 h and 72 h (12.67 ± 0.40, *p* = 0.001 and 15.00 ± 0.33, *p* = 0.000, respectively) ([Figure 7](#ijms-18-00854-f007){ref-type="fig"}B,C). RES treatment (12.50 ± 0.36, *p* = 0.016 and 14.83 ± 0.39, *p* = 0.002) increased the neurological scores compared with those of the NS group (11.16 ± 0.37 and 12.83 ± 0.44) at 24 h and 72 h ([Figure 7](#ijms-18-00854-f007){ref-type="fig"}B,C). However, there was no significant difference between the scores of the GSK2656157 (12.58 ± 0.36, *p* = 0.133 and 15.58 ± 0.31, *p* = 0.068) and DMSO (11.18 ± 0.32 and 14.58 ± 0.42, [Figure 7](#ijms-18-00854-f007){ref-type="fig"}B,C) control groups. These results suggested that TXNIP inhibition could attenuate the neurological deficits of SAH rats, but PERK inhibition showed no significant improvement.

2.7. BBB Permeability {#sec2dot7-ijms-18-00854}
---------------------

Evans blue dye extravasation was used to measure the BBB permeability after SAH. In comparison to the sham group, SAH caused remarkable extravasation of Evans blue dye in the cerebral hemispheres, the cerebellum (CB), and the brain stem (BS) 72 h post-surgery ([Figure 7](#ijms-18-00854-f007){ref-type="fig"}D, *p* \< 0.05). TXNIP siRNA injection significantly prevented BBB disruption in comparison to the control group, as reflected by the reduced amount of Evans blue dye in the left hemisphere (LH), right hemisphere (RH), and CB at 72 h ([Figure 7](#ijms-18-00854-f007){ref-type="fig"}D, *p* \< 0.05). In addition, BBB disruption was also attenuated by RES injection in three brain regions (LH, RH, and CB) ([Figure 7](#ijms-18-00854-f007){ref-type="fig"}D, *p* \< 0.05). Simultaneously, GSK2656157 treatment alleviated BBB disruption compared with the disruption observed in the DMSO control group ([Figure 7](#ijms-18-00854-f007){ref-type="fig"}D, *p* \< 0.01). However, there were no significant differences in Evans blue dye extravasation in the BS between each group. These results showed that the inhibition of TXNIP and PERK could prevent BBB disruption in different regions after SAH.

2.8. Brain Water Content {#sec2dot8-ijms-18-00854}
------------------------

SAH has been shown to cause marked brain edema in animal experiments, and diffuse brain swelling was also observed in this study at 72 h post-surgery. In comparison to the sham group, the brain water content was significantly deteriorated in the LH, RH, and CB at 72 h ([Figure 7](#ijms-18-00854-f007){ref-type="fig"}E and [Table S1](#app1-ijms-18-00854){ref-type="app"}, *p* \< 0.05). However, no significant differences in the BS were found between groups ([Figure 7](#ijms-18-00854-f007){ref-type="fig"}E, *p* = 0.310). SAH rats treated with RES exhibited lower brain water content in LH, RH, and CB when compared with rats in the NS group ([Figure 7](#ijms-18-00854-f007){ref-type="fig"}E and [Table S1](#app1-ijms-18-00854){ref-type="app"}, *p* \< 0.05). Additionally, the TXNIP siRNA treatment significantly reduced the water content in the LH, RH, and CB when compared with that in the control siRNA group ([Figure 7](#ijms-18-00854-f007){ref-type="fig"}E and [Table S1](#app1-ijms-18-00854){ref-type="app"}, *p* \< 0.001). The brain water content was also significantly reduced by GSK2656157 in comparison to the DMSO control group ([Figure 7](#ijms-18-00854-f007){ref-type="fig"}E and [Table S1](#app1-ijms-18-00854){ref-type="app"}, *p* = 0.001). These results demonstrated that TXNIP and PERK inhibition could reduce cerebral edema after SAH.

3. Discussion {#sec3-ijms-18-00854}
=============

The present study proves that both pharmacological inhibition and gene knockdown of TXNIP significantly attenuated apoptosis and early prognostic symptoms after SAH. We found that these effects were closely associated with the TXNIP proapoptotic signalling pathway. For the first time, we found that TXNIP was extensively colocalized with TUNEL-positive cells in the rat hippocampus and subcortex after SAH. Meanwhile, PERK inhibition also showed significant TXNIP suppression and apoptosis attenuation. Together, our findings support the hypothesis that TXNIP may be a new effective target for EBI treatment after SAH.

Apoptosis is an important pathophysiological process of EBI that occurs rapidly in the SAH brain. Neurons, as well as astrocytes, oligodendrocytes, and vascular smooth muscle and endothelial cells, undergo apoptosis 24 h after SAH \[[@B20-ijms-18-00854],[@B21-ijms-18-00854]\]. Various pro-apoptotic mechanisms are believed to be involved in EBI after SAH \[[@B1-ijms-18-00854],[@B21-ijms-18-00854],[@B22-ijms-18-00854]\]. Caspase-dependent intrinsic pathway activation is considered to be the major factor that causes apoptosis, which not only includes the activation of proapoptotic proteins (BID, BAX, BAK, BAD, and BCL-XS), but also the inhibition of antiapoptotic proteins (BCL-2 and BCL-XL) \[[@B1-ijms-18-00854],[@B21-ijms-18-00854],[@B22-ijms-18-00854]\].

Previous studies have reported that TXNIP is proapoptotic in ischaemic diseases \[[@B6-ijms-18-00854],[@B7-ijms-18-00854],[@B12-ijms-18-00854]\]. However, whether or not TXNIP also influences the effect of SAH is still unknown. Kaya and colleagues reported that SAH significantly induced TXNIP mRNA expression \[[@B23-ijms-18-00854]\]. Therefore, we speculated that TXNIP may also participate in EBI. TXNIP was first known as an endogenous inhibitor of cellular TRX that binds directly to TRX and exerts a proapoptotic function under pathologic conditions \[[@B24-ijms-18-00854],[@B25-ijms-18-00854],[@B26-ijms-18-00854]\]. TRX1 is one of the TRX proteins that have various biological functions and can integrate with and inhibit ASK-1-dependent apoptosis \[[@B24-ijms-18-00854]\]. TRX inhibition can induce neuronal apoptosis after cerebral ischaemia, which is extremely relevant to SAH-induced EBI \[[@B10-ijms-18-00854],[@B27-ijms-18-00854]\]. Similarly, we found that TRX1 expression was inhibited after SAH ([Figure 2](#ijms-18-00854-f002){ref-type="fig"}), as TXNIP may colocalize with TRX1 and suppress TRX1 transcription \[[@B27-ijms-18-00854]\]. Kim and colleges reported that TXNIP is proapoptotic and is located in neurons under ischaemic conditions \[[@B12-ijms-18-00854]\]. In this study, we also found that TXNIP was widely expressed in neurons of the SAH rat brain ([Figure 3](#ijms-18-00854-f003){ref-type="fig"}A). More importantly, our TUNEL staining demonstrated for the first time that TXNIP was widely colocalized with apoptosis-positive cells both in the hippocampus and cortex after SAH ([Figure 3](#ijms-18-00854-f003){ref-type="fig"}B). These results may be the critical evidence necessary to further support our speculation. In the next experiment, when TXNIP expression was downregulated, cell apoptosis was significantly reduced, and the prognostic indicators of SAH were attenuated. Taken together, TXNIP may be associated with brain cell apoptosis in EBI after SAH. Although TXNIP is a promising therapeutic target, the application of TXNIP-specific inhibitors and agonists may be far more convincing in our study.

We previously found that sustainable PERK-C/EBP-homologous protein (CHOP) signalling activation could promote neuronal apoptosis after SAH \[[@B3-ijms-18-00854],[@B11-ijms-18-00854]\]. As an important ER stress-related downstream signalling pathway, PERK-CHOP signalling is required at ER-mitochondrial contact sites to convey apoptosis \[[@B19-ijms-18-00854],[@B28-ijms-18-00854]\]. Interestingly, irremediable ER stress can rapidly promote TXNIP upregulation \[[@B8-ijms-18-00854],[@B29-ijms-18-00854]\]. Specifically, Oslowski and colleagues found that PERK significantly promoted TXNIP expression through ATF-5 and ChREBP transcription factors under ER stress \[[@B8-ijms-18-00854]\]. The ER is the primary location for protein folding, posttranslational modification, and assembly \[[@B30-ijms-18-00854]\]. Various stimuli, such as hypoxia and oxidative stress, can result in ER stress, which is a self-protective signal transduction pathway at first \[[@B31-ijms-18-00854],[@B32-ijms-18-00854]\]. However, a high level of ER stress can culminate in cell death through promoting CHOP apoptosis signalling pathway activation \[[@B33-ijms-18-00854],[@B34-ijms-18-00854]\]. Simultaneously, an increasing number of studies have shown that ER stress is implicated in the pathogenesis of cerebral ischaemia and SAH \[[@B3-ijms-18-00854],[@B35-ijms-18-00854]\]. Our results found that PERK inhibition resulted in brain protection through the downregulation of TXNIP expression. Unfortunately, we did not detect the dose-dependent change of TXNIP and downstream apoptotic associated factors induced after GSK2656157 intervention, and we also did not measure the mRNA and immunofluorescence change of TXNIP after TXNIP siRNA and RES intervention, which would be more beneficial to confirm our conclusion. Meanwhile, as one of the limitations of the current study, we only tested the PERK phosphorylation levels. A more thorough method is to detect the total-PERK levels and then calculate the ratios between the p-PERK and total-PERK, which would provide more favourable evidence to support our results. Therefore, in a sense, these findings might indirectly suggest a potential link between ER stress, TXNIP, and SAH. Stress in the ER, as an important organelle in cells, might be a novel therapeutic target in SAH-related brain injury. These are shortcomings of this current study design and more work need to be done in our future work.

Activated PERK phosphorylates the eukaryotic translation initiation factor-2α (eIF-2α), inducing CHOP, ATF-5, and ChREBP expression \[[@B36-ijms-18-00854]\]. In this study, PERK inhibition protected SAH-induced brain injury, but we could not exclude the possibility that some other mechanisms also exist. For example, Yan and colleagues found that PERK inhibition also exerts neuroprotective effects through Akt activation \[[@B37-ijms-18-00854]\], which may explain why PERK inhibition did not attenuate the neurological deficits in our study. Meanwhile, other mechanisms also participate in the regulation of TXNIP expression and still deserve our further attention. Complementary to our results, Lerner and colleagues reported that hyperactivated inositol-requiring enzyme1α (IRE1α), a protein in the ER transmembrane like PERK, can also induce TXNIP expression at the posttranscriptional level through selective decay of TXNIP-destabilizing microRNA-17 \[[@B29-ijms-18-00854]\]. More interestingly, TXNIP has been confirmed to participate in inflammatory amplification by activating the Nod-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome \[[@B38-ijms-18-00854]\]. Currently, both proinflammatory and proapoptotic factors have been demonstrated to be involved in SAH-induced brain injury \[[@B21-ijms-18-00854]\]. In addition, ER stress can also occur in other pro-inflammatory immune or supporting cell types of the neurovascular unit, such as astrocytes, oligodendrocytes, vascular smooth muscle, and endothelial cells. It is also possible that ER-stress might induce pro-inflammatory activation of other cell types, which then can mediate indirect activation of TXNIP in neuronal cells in a paracrine matter. Finally, TXNIP possesses many kinds of biological functions and is important in multiple signalling pathways, which are worth researching thoroughly. Certainly, there are still many experiments that need to be done.

4. Materials and Methods {#sec4-ijms-18-00854}
========================

4.1. Animals {#sec4dot1-ijms-18-00854}
------------

Two hundred fifty-nine adult male Sprague--Dawley rats (280--350 g) were obtained from the Animal Center of Chongqing Medical University. Animals were maintained in a specific pathogen-free laboratory with regular 12/12 h light/dark cycles under controlled temperature and humidity conditions. The Animal Ethics and Use Committee of Chongqing Medical University approved all experimental procedures (Permit No. SCXK (Chongqing) 2007-0001). All surgical procedures were performed under deep anaesthesia to minimize suffering, in accordance with the recommendation guidelines in the Care and Use of Laboratory Animals of the National Institutes of Health. Rats were divided into different groups: sham (*n* = 33), SAH (*n* = 63), SAH + control siRNA (Control, *n* = 23), SAH + TXNIP siRNA (*n* = 21), SAH + normal saline (NS, as a vehicle, *n* = 24), SAH + resveratrol (RES, *n* = 22), SAH + dimethyl sulfoxide (DMSO, as a vehicle, *n* = 28), and SAH + GSK2656157 (GSK, *n* = 45).

4.2. Endovascular Perforation Model of SAH {#sec4dot2-ijms-18-00854}
------------------------------------------

The endovascular perforation model is considered to be the most suitable model of SAH, given that there are many similarities in the pathophysiological changes observed with a clinical ruptured intracranial aneurysm \[[@B39-ijms-18-00854]\]. SAH animal models were established through endovascular perforation as described before \[[@B40-ijms-18-00854]\]. Rats were anaesthetized with an intraperitoneal injection of sodium pentobarbital (50 mg/kg), and supplemental doses (5 mg/kg) of pentobarbital were given to maintain anaesthesia when necessary. Body temperature was maintained at 37 °C using an electric heating pad during the operation. Sham-operated rats underwent identical procedures without the vessel puncture. After perforation, rats were kept in heated cages until recovery from anaesthesia.

4.3. Drug Administration {#sec4dot3-ijms-18-00854}
------------------------

### 4.3.1. Resveratrol and TXNIP siRNA Injection {#sec4dot3dot1-ijms-18-00854}

Resveratrol (trans-3,4′,5-trihydroxystilbene, RES) was delivered to rats by intraperitoneal injection 1 h after puncture with a single dose of 60 mg/kg (1 mL, Sigma-Aldrich, St. Louis, MO, USA, −20 °C) \[[@B16-ijms-18-00854]\]. RES, which is a natural phytoalexin in red wine, grape skin, and other plants with the ability to penetrate the BBB and rapidly reach brain tissue \[[@B14-ijms-18-00854]\], has been reported to significantly suppress TXNIP mRNA and protein expression \[[@B7-ijms-18-00854],[@B15-ijms-18-00854]\]. RES was dissolved in 50% ethanol and diluted with physiological saline. Normal saline (1 mL) containing 50% ethanol was used as the control.

Rats received TXNIP siRNA and control siRNA 24 h before the operation through intracerebroventricular infusion, as previously described \[[@B3-ijms-18-00854]\]. Two different TXNIP siRNA were designed, as described before \[[@B17-ijms-18-00854],[@B18-ijms-18-00854]\], and obtained from RiboBio Co., Ltd. (Guangzhou, China, [Table 1](#ijms-18-00854-t001){ref-type="table"}). Briefly, 5 nmol siRNA mixture per rat in 6 μL of sterile phosphate-buffered saline (PBS) was inserted into the left lateral ventricle through a burr hole with a sterile 10-μL Hamilton syringe at a rate of 0.5 μL/min with the coordinates of 1.5 mm posterior, 1.0 mm lateral, and 3.2 mm below bregma in the horizontal plane \[[@B3-ijms-18-00854]\]. Sham and SAH animals also received a burr hole, but no siRNA injection was performed. Ten minutes later, the needle was removed and the burr hole was carefully plugged with bone wax.

### 4.3.2. GSK2656157 Injection {#sec4dot3dot2-ijms-18-00854}

GSK2656157 (MedChem Express, HY-13820, Shanghai, China) is an adenosine triphosphate (ATP)-competitive inhibitor that has been reported to effectively suppress PERK autophosphorylation through interaction with the PERK kinase domain \[[@B41-ijms-18-00854]\]. However, the use of GSK2656157 in animal brain has not been reported. To avoid the necessity of the drug to cross the BBB and to improve the local drug concentration, SAH rats also received GSK2656157 through intracerebroventricular injection at the same coordinates as the TXNIP siRNA injection. According to a previous study, GSK2656157 can completely inhibit PERK autophosphorylation 8 h after treatment \[[@B41-ijms-18-00854]\]. GSK2656157 was injected twice through two bilateral burr holes 8 h before and after surgery. Briefly, 10 μL of 1% DMSO in saline containing 30, 60, 120, 180, 240, or 300 μg of GSK2656157 were injected under deep anaesthesia with a sterile 10-μL Hamilton syringe at a rate of 0.5 μL/min. Ten minutes later, the needle was removed and the burr hole was plugged with bone wax. Rats in the control group received 10 μL of 1% DMSO in saline without the inhibitor. Under deep anaesthesia 24 h after surgery, the rats were quickly decapitated for western blot.

4.4. Neurological Scores {#sec4dot4-ijms-18-00854}
------------------------

Neurological scores were evaluated at 24 and 72 h in a blinded fashion according to the scoring methods reported before \[[@B42-ijms-18-00854]\]. An 18-point scoring system was used that consisted of six subtests, including spontaneous activity, spontaneous movements of four limbs, outstretching of the forelimbs, wall climbing of a wire cage, the trunk-touch reaction, and the vibrissae-touch response. Lower scores indicated serious neurological deficits.

4.5. SAH Grade and Mortality {#sec4dot5-ijms-18-00854}
----------------------------

After the evaluation of the neurological scores, rats were sacrificed to quantify the severity of SAH according to the previously described grading scale \[[@B42-ijms-18-00854]\]. Each rat obtained a total score ranging from 0 to 18 after adding scores from all six subtests. Animals with a score below 5 points were ruled out due to their low SAH grade \[[@B42-ijms-18-00854]\]. Meanwhile, mortality was recorded after the operation.

4.6. Blood-Brain Barrier (BBB) Permeability {#sec4dot6-ijms-18-00854}
-------------------------------------------

BBB permeability assessment was based on Evans blue extravasation \[[@B43-ijms-18-00854]\]. At 72 h after perforation, 4% Evans blue dye (2.5 mL/kg) was injected into the left femoral vein under deep anaesthesia and allowed to circulate for 60 min. Spectrophotometry was used to quantify the Evans blue dye at an excitation wavelength of 620 nm, an emission wavelength of 680 nm and a bandwidth of 10 nm.

4.7. Brain Water Content {#sec4dot7-ijms-18-00854}
------------------------

Under deep anaesthesia, 72 h after perforation, the brains were quickly divided into the LH, RH, CB, and BS. These portions were weighed immediately (wet weight) and then kept in the oven for 72 h at 105 °C (dry weight). The brain water content percentage was recorded using the following equation: (wet weight to dry weight)/wet weight × 100% \[[@B3-ijms-18-00854]\].

4.8. Immunofluorescence {#sec4dot8-ijms-18-00854}
-----------------------

Animals were sacrificed 24 h after perforation for immunofluorescence in accordance with our previous study \[[@B3-ijms-18-00854]\]. Ten-micron-thick sections of SAH rat brains were incubated with primary antibodies against the following proteins (TXNIP (1:50, Abcam, Cambridge, MA, USA) and NEUN (1:100, Merck Millipore, Billerica, MA, USA) overnight at 4 °C. Fluorescence microscopy (FV1200, Olympus, Tokyo, Japan) was used to detect the localization of TXNIP in neurons. For negative controls, the same staining procedures were conducted without primary antibodies.

4.9. TUNEL Staining {#sec4dot9-ijms-18-00854}
-------------------

Fluorescent TUNEL staining (Roche Inc., Mannheim, Germany) was performed according to the manufacturer's protocol and a previous study \[[@B40-ijms-18-00854]\]. TUNEL staining was used to detect TXNIP localization with apoptotic cells in the hippocampus and cortex of SAH animals by using fluorescence microscopy (IX71, Olympus, Japan). TUNEL-positive cells in the ipsilateral basal cortex (left) in five different fields per animal were counted under microscopy under 400× magnification in a blinded manner. The number of TUNEL-positive cells/mm^2^ predicted the severity of brain injury \[[@B44-ijms-18-00854]\]. Meanwhile, negative controls were performed with labelling solution without the TUNEL reagent.

4.10. Western Blot {#sec4dot10-ijms-18-00854}
------------------

Under deep anaesthesia, rats were quickly decapitated, and the LHs were isolated for western blot, as described before \[[@B45-ijms-18-00854]\]. Polyvinylidene fluoride (PVDF) membranes were incubated with primary antibodies against the following proteins: TXNIP (1:500; Abcam, Cambridge, MA, USA), TRX1 (1:2000; Abcam), ASK-1 (1:1000; Cell Signaling Technology, CST, Danvers, MA, USA), phosphorylated-ASK-1 (p-ASK-1,1:5000; Sigma-Aldrich, St. Louis, MO, USA), CC3 (1:1000; CST), BCL-2 (1:1000; CST), BAX (1:2000; Abcam), phosphorylated--PERK (p-PERK, 1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA), eIF2α (1:100; Santa Cruz), phosphorylated-eIF2α (p-eIF2α, 1:500; Abcam), ChREBP (1:100; Santa Cruz), ATF-5 (1:2000; Abcam), and β-actin (NeoBioscience Technology Co., Ltd., Beijing, China). Membranes were incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies, visualized with the enhanced chemiluminescent reagent kit (ECL, Engreen Biosystem Co., Ltd., Beijing, China), and analysed with a Fusion gel imaging apparatus (Fusion fx 7 Spectra, Vilber, France). The results are expressed as a percentage of the values of β-actin.

4.11. Statistical Analysis {#sec4dot11-ijms-18-00854}
--------------------------

Statistical analysis was performed using SPSS17.0 software. The mortality data were analysed by Fisher's exact test. All of the other data were expressed as the mean ± standard error of the mean, and t comparisons among multiple groups were performed by one-way analysis of variance (ANOVA), and followed by Dunnett's *t*-test to compare between the control group and treatment group and the Student-Newman-Keuls test for between the two treatment groups with different intervention. *p* \< 0.05 was considered to be statistically significant.

5. Conclusions {#sec5-ijms-18-00854}
==============

TXNIP may participate in EBI after SAH by mediating brain cell apoptosis. The blockage of TXNIP induced by PERK attenuated cell apoptosis and brain edema and improved the neurological score of SAH rats. Multiple independent proteins or interconnected signalling pathways may participate in the pathological process of EBI after SAH. These results suggest that TXNIP inhibition may be a potential therapeutic strategy after SAH.
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![Experimental design (**A**--**C**). SD rats, Sprague--Dawley rats; SAH, subarachnoid haemorrhage; NS, SAH + normal saline; RES, SAH + resveratrol; Control, SAH + control siRNA; siRNA, small interfering RNA; BBB, blood-brain barrier; DMSO, dimethyl sulfoxide; TXNIP, thioredoxin-interacting protein; PERK, protein kinase RNA-like endoplasmic reticulum (ER) kinase.](ijms-18-00854-g001){#ijms-18-00854-f001}

![The expression of TXNIP and apoptosis proteins at different time points after SAH. (**A**) Representative western blot of TXNIP, thioredoxin 1 (TRX1), p-ASK-1/ASK-1, cleaved caspase-3 (CC3), B-cell lymphoma (BCL)-2-associated X protein (BAX), and BCL-2; (**B**--**G**) Densitometric quantification of the protein band optical densities for TXNIP and associated proteins. TXNIP expression increased significantly after SAH and was accompanied by an increased expression of apoptosis proteins and decreased expression of anti-apoptotic proteins. \# sham vs. SAH at 24 h, *p* \< 0.05. ASK-1, apoptosis signal-regulating kinase-1.](ijms-18-00854-g002){#ijms-18-00854-f002}

![The histological fluorescent analysis of TXNIP and immunofluorescence Terminal dexynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) staining with TXNIP. (**A**) TXNIP was colocalized with NEUN-positive cells (the neurons) (*n* = 3, detected by fluorescence microscopy, FV1200, Olympus, Japan). TXNIP (green), NEUN (red), DAPI (4′,6-diamidino-2-phenylindole, the nucleus, blue), and original magnification ×1200; (**B**) TXNIP was colocalized with TUNEL-positive cells in the hippocampus and subcortex (*n* = 3, detected by fluorescence microscopy, IX71, Olympus, Japan). TXNIP (red), TUNEL (green), DAPI (the nucleus, blue), original magnification of the subcortex (×200) and hippocampus (×400). Scale bars: (**A**) = 20 μm, (**B**) = 120 μm (**top**) and 60 μm (**bottom**).](ijms-18-00854-g003){#ijms-18-00854-f003}

![TXNIP and apoptosis protein expression, and the number of TUNEL-positive cells after TXNIP siRNA and RES treatment. (**A**--**F** and [Figures S1 and S2](#app1-ijms-18-00854){ref-type="app"}) Representative western blot and densitometric quantification of protein band optical densities for TXNIP, TRX1, p-ASK-1/ASK-1, CC3, BAX, and BCL-2. TXNIP and apoptosis protein expression levels were downregulated by TXNIP siRNA and RES treatment; (**G**,**H**) The number of TUNEL-positive cells decreased after siRNA and RES treatment. Original magnification, ×400; scale bars: **G** = 60 μm. \# *p* \< 0.05 vs. SAH + control siRNA, & *p* \< 0.05 vs. SAH + NS.](ijms-18-00854-g004){#ijms-18-00854-f004}

![GSK2656157 treatment suppressed the autophosphorylation of PERK in a dose-dependent manner, as well as the expression of p-eIF2α/eIF2α, ATF-5, and ChREBP. (**A**--**E**) Representative western blot of p-PERK, p-eIF2α/eIF2α, ATF-5, and ChREBP. \# *p* \< 0.05 vs. SAH + DMSO.](ijms-18-00854-g005){#ijms-18-00854-f005}

![GSK2656157 treatment suppressed TXNIP expression and the number of TUNEL-positive cells. (**A**--**D**, and [Figure S3](#app1-ijms-18-00854){ref-type="app"}) Representative western blot of p-PERK, TXNIP, p-eIF2α/eIF2α, ATF-5, and ChREBP; (**D**,**E**) The number of TUNEL-positive cells decreased by the GSK2656157 treatment. Original magnification, ×400 (*n* = 5, each group); scale bars: (**E**) = 60 μm. \* *p* \< 0.05 vs. Sham, \# *p* \< 0.05 vs. SAH + DMSO.](ijms-18-00854-g006){#ijms-18-00854-f006}

![The SAH grade, neurological deficits, blood-brain barrier (BBB) permeability, and brain water content. (**A**) SAH grading scores were similar among each surgery group; (**B**,**C**) TXNIP siRNA and RES increased the neurological score, but GSK2656157 treatment did not result in significant improvement in the neurological deficits compared with the control group; (**D**) BBB disruption was also attenuated in three sections after TXNIP siRNA, RES, and GSK2656157 treatment; (**E** and [Table S1](#app1-ijms-18-00854){ref-type="app"}) The brain water content was reduced by TXNIP siRNA, RES, and GSK2656157 treatment. @ *p* \< 0.05 vs. Sham; \# *p* \< 0.05 vs. SAH + control siRNA, & *p* \< 0.05 vs. SAH + NS, \* *p* \< 0.05 vs. SAH + DMSO.](ijms-18-00854-g007){#ijms-18-00854-f007}
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###### 

The sequences of the two different TXNIP siRNAs.

  ---------------------------------------------------------------------------
  Name                               Sequences
  ---------------------------------- ----------------------------------------
  siRNA 1 \[[@B17-ijms-18-00854]\]   sense: 5′-GCUGG AUAGACCUAAACAUTT-3′\
                                     antisense: 5′-AUGUUUAGGUCUAUCCAGCTT-3′

  siRNA 2 \[[@B18-ijms-18-00854]\]   sense: 5′-UGGUCACGUCGAAAUGAAUTT-3′\
                                     antisense: 5′-TTACCAGUGCAGCUUUACUUA-3′

  Control siRNA                      sense: 5′-UUCUCCGAACGUGUCACGUTT-3′\
                                     antisense: 5′-ACGUGACACGUUCGGAGAATT-3′
  ---------------------------------------------------------------------------
